<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598130</url>
  </required_header>
  <id_info>
    <org_study_id>FL-PN-002-IS</org_study_id>
    <secondary_id>MoH</secondary_id>
    <nct_id>NCT00598130</nct_id>
  </id_info>
  <brief_title>Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy</brief_title>
  <acronym>Fleece</acronym>
  <official_title>A Prospective, Randomized, Single-Blind, Standard Care Controlled, Multi-Center, Phase II Study Evaluating the Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OMRIX Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OMRIX Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single blind, standard care- controlled study, which will
      include a total of 30 patients divided into two treatment arms: First are: patents who will
      be treated in accordance with standard of care. Second arm: patients for which the Fibrin
      Fleece will be applied directly on the active bleeding site.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of successes at 10 minutes following randomization</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of successes at 5 minutes following randomization</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemostatic Techniques</condition>
  <condition>Nephrectomy</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who will be treated in accordance with standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients for which the Fibrin Fleece will be applied directly on the active bleeding site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fleece</intervention_name>
    <description>Fibrin Patch</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective open partial nephrectomy

          -  Patients must be willing to participate in the study, and provide written informed
             consent

        Exclusion Criteria:

          -  Patients with a tumor diameter greater than 4 cm

          -  Any additional surgical intervention other than partial nephrectomy

          -  Patients with only one functional kidney

          -  Patients with known intolerance to blood products or other components of the product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoram Dekel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnei-Zion MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir MC</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin MC</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheaba MC</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>November 5, 2009</last_update_submitted>
  <last_update_submitted_qc>November 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eran Kurman - Clinical Affaires Manager</name_title>
    <organization>Omrix Biopharmaceuticals</organization>
  </responsible_party>
  <keyword>Patients undergoing elective open partial nephrectomy surgery</keyword>
  <keyword>Excision of a kidney</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

